Life Science News

Optimi Health Corp . ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a homegrown, Canadian company producing natural, scalable, and accessible psychedelic and functional mushrooms, as well as synthetic formulations for transformational human experiences, is pleased to announce that it has entered into a supply agreement with SABI Mind, a Calgary-based clinic group providing psychedelic-assisted therapies.

The Company has signed an agreement which will provide SABI Mind's trained clinical staff with supplies of GMP psilocybin and 3,4-Methylenedioxymethamphetamine ("MDMA"), pending the anticipated approval of its previously announced licensing amendment, for use by practitioners in psychedelic-assisted therapeutic protocols with approved patients via Health Canada's Special Access Program, clinical trials, and academic studies.

"This agreement is an important step forward for both parties," said Optimi Health CEO Bill Ciprick. "SABI Mind's initiation of this agreement demonstrates a commitment to safe supply for the development and implementation of therapeutic modalities using psilocybin and MDMA."

Clinical distribution is a major milestone in the growth of Canada's psychedelics sector from the standpoints both of business operations, and as a medical option for those in need.

"There's growing evidence that MDMA and psilocybin assisted therapies can help treat PTSD, depression and other chronic mental health conditions," said Philippe Lucas PhD, SABI Mind President. "We're very pleased to be working with Optimi to ensure a safe, consistent supply of psilocybin and MDMA to SABI patients qualifying under Health Canada's Special Access Program."

"As we continue to establish the logistical channels of our new industry, Optimi is extremely gratified to receive requests such as this," added Ciprick. "The knowledge that the substances we produce, natural or synthetic, will be used by patients in a safe environment to further psychedelic science is a vindication of the principles on which this company was established."

Optimi Health recently requested an amendment to its Controlled Substance Dealer's Licence from Health Canada which would enable it to utilize its state-of-the-art analytical laboratory for the production of synthetic MDMA, among other substances.

SABI Mind currently operates a best-in-class clinic in the Sunalta area of Calgary, with expansions planned into Edmonton, Alberta and Victoria, British Columbia.

Authorized parties interested in purchasing Optimi psilocybin and functional mushroom products, MDMA, or other synthetic psychedelics are invited to contact sales@optimihealth.ca where a member of the sales team will respond within 24 hours.

ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)

Optimi Health Corp. is a homegrown, Canadian success story producing and supplying natural, EU-GMP grade psilocybin and functional mushrooms that focus on the health and wellness markets. Built with the purpose of producing scalable, natural mushroom formulations for transformational human experiences, the Company's goal is to be the number one trusted, compassionate supplier of safe, natural EU-GMP psilocybin throughout the world. With a vertically integrated approach, Optimi is engaged in the cultivation, extracting, processing and distribution of high quality functional and psychedelic mushroom products at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia.

About SABI Mind

Located in Calgary, SABI Mind supports the careful and necessary mending of mental health and chronic pain through psychedelic-assisted therapies. Founded by a group of Calgary-based entrepreneurs brought face-to-face with the challenges of those suffering from mental health conditions, SABI Mind empowers those discouraged by the conventional medical methods with a patient-centered treatment model supported by experienced psychiatrists, anesthesiologists, therapists, client experience specialists, and other clinic staff specially trained in ketamine-assisted psychotherapy and other psychedelic therapies.

FOR INTERVIEW REQUESTS OR FURTHER INFORMATION PLEASE CONTACT:

Investor Relations
Michael Kydd
Email: investors@optimihealth.ca
Phone: +1 (902) 880 6121
Web: https://optimihealth.ca

FORWARD‐LOOKING STATEMENTS

This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, "forward‐looking statements") that relate to Optimi's current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as "will likely result," "are expected to," "expects," "will continue," "is anticipated," "anticipates," "believes," "estimated," "intends," "plans," "forecast," "projection," "strategy," "objective," and "outlook") are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward‐ looking statements pertaining to activities proposed to be conducted under the Company's dealer's license and associated business related to Psilocybin and Psilocin and Optimi's plans, focus and objectives.

Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under "Forward‐Looking Statements" and "Risk Factors" in the Company's Annual information Form dated January 12, 2022, and other continuous disclosure filings available under Optimi's profile at www.sedar.com. Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement.

Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/67fd5330-02d3-40bb-af5b-938cb2c94f6d

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/49bf2da6-a0b2-481e-9cf3-eed6879d5af7


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

OPTI:CC
Optimi Health

Optimi Health


Keep reading...Show less
Optimi Health To Launch Therapeutic Psilocybin Product In Partnership With Patient Advocate Thomas Hartle

Optimi Health To Launch Therapeutic Psilocybin Product In Partnership With Patient Advocate Thomas Hartle

Optimi Health Corp. ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a homegrown, Canadian company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushrooms, as well as synthetic formulations for transformational human experiences, is pleased to announce that it has entered into a partnership with psilocybin patient advocate, Thomas Hartle. The parties have agreed to produce a Canadian-grown and harvested natural therapeutic psilocybin product for use by approved patients.

"Honouring Thomas's incredible optimism and appreciation for life with his own natural, Canadian-grown psilocybin product is something we will cherish as a company forever," said Bill Ciprick, CEO of Optimi Health. "We share Thomas's energy and passion for creating the perfect psilocybin experience, and we look forward to providing a vital service to Special Access Program patients while further demonstrating to regulators that psychedelic-assisted therapies can be integrated into our existing healthcare framework."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Optimi Health Finalizes Psilocybin Supply Agreement With Bloom Psychedelic Therapy And Research Centre

Optimi Health Finalizes Psilocybin Supply Agreement With Bloom Psychedelic Therapy And Research Centre

Optimi Health Corp. ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a homegrown, Canadian company cultivating and synthesizing high quality psychedelics and natural functional and psilocybin mushroom strains for transformational human experiences, is pleased to announce that it has finalized a supply agreement with Bloom Psychedelic Therapy And Research Centre ("Bloom"), a Calgary-based provider of mental health services, including psychedelic-assisted therapies employing ketamine treatments.

"Our Supply Agreement with Bloom solidifies another key relationship for Optimi," said CEO Bill Ciprick. "Their position as therapeutic practitioners, as well as their work in conducting the kind of clinical trials necessary to advance regulatory outcomes for psychedelic medicines, make them ideal partners in alignment with Optimi's strategic goals."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Optimi Health Requests Approval To Manufacture MDMA, Other Synthetic Psychedelics

Optimi Health Requests Approval To Manufacture MDMA, Other Synthetic Psychedelics

Optimi Health Corp . ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, has submitted a request with Health Canada for an amendment to its Controlled Substances Dealer's Licence.

The amendment would enable the Company to synthesize, process and distribute pharmaceutical grade 3,4-Methylenedioxymethamphetamine ("MDMA"), among other substances, at its Princeton, British Columbia facility.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Optimi Health Finalizes Partnership and Psilocybin Supply Agreement With ATMA Journey Centers

Optimi Health Finalizes Partnership and Psilocybin Supply Agreement With ATMA Journey Centers

Optimi Health Corp. ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce that it has entered into an exploratory supply agreement with ATMA Journey Centers ("ATMA"), a privately held facilitator of psilocybin-assisted therapy and practitioner training services for palliative care and mental health conditions based in Calgary, Alberta.

The Company has finalized an agreement which will supply psilocybin products to ATMA for future therapist initiatives and supply requirements.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Optimi Health Enters Into Psilocybin Supply Agreement With Filament Health

Optimi Health Enters Into Psilocybin Supply Agreement With Filament Health

Optimi Health Corp. ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce that it has entered into a supply agreement with Filament Health ("Filament") (OTCQB:FLHLF) (NEO:FH) (FSE:7QS), a clinical-stage natural psychedelic drug development company.

Optimi has been engaged by Filament to supply psilocybin mushrooms cultivated in Optimi's recently inaugurated 20,000 square foot EU-GMP Princeton, British Columbia facility in the form of whole, dried mushroom fruiting bodies for potential drug development, testing, and analysis by Filament's research team.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

COMPASS Pathways plc announces second quarter 2022 financial results and business highlights

-

Highlights:
  • Kabir Nath appointed as Chief Executive Officer
  • Phase III program submitted to FDA and under review
  • COMP360 phase II study in anorexia nervosa launched
  • Cash position at 30 June 2022 of $207.2 million
  • Conference call today at 8:00am ET (1:00pm UK)

COMPASS Pathways plc (Nasdaq: CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the second quarter 2022 and gave an update on recent progress across its business.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Morgan Stanley Positive in First Psychedelics Research Report

Morgan Stanley Positive in First Psychedelics Research Report

Morgan Stanley (NYSE:MS) has shared its first official commentary on the psychedelics industry.

The concept of investing in psychedelic medicine received a legitimate vote of confidence of sorts after the well-established banking firm released an introductory study evaluating the potential attached to the sector.

The research is intended to offer an initial look at the psychedelics investment proposal.

Keep reading...Show less

COMPASS Pathways Announces Grant of Inducement Award for Newly Appointed Chief Executive Officer Pursuant to Nasdaq Listing Rule 5635

COMPASS Pathways plc (Nasdaq: CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that COMPASS granted a non-qualified share option to purchase an aggregate of 600,000 ordinary shares, nominal value £0.008 each, in the capital of the Company to Kabir Nath, COMPASS's newly appointed chief executive officer. In accordance with NASDAQ Listing Rule 5635(c)(4), the non-qualified share option award was approved by the Compensation and Leadership Development Committee of COMPASS's Board of Directors and made as a material inducement to Kabir's entry into employment with COMPASS as its new chief executive officer.

The non-qualified share option was granted on August 1, 2022 and has an exercise price per share equal to $14.94, the closing price of the Company's American Depositary Shares on the Nasdaq Global Select Market on the grant date. The non-qualified share option has a 10-year term and vests as to one-fourth on August 1, 2023 (the first anniversary of his employment commencement date) and as to the remaining three-fourths in equal monthly installments over the following 36 months, subject to Kabir remaining an employee of the Company on the applicable vesting dates. The non-qualified share option has other terms that mirror those of non-qualified share options granted under COMPASS's 2020 Share Option and Incentive Plan and COMPASS's standard form of non-qualified share option agreement.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

COMPASS Pathways to participate in upcoming BTIG Biotechnology Conference and Canaccord Annual Growth Conference

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in two upcoming events as follows:

  • BTIG Biotechnology Conference: host investor meetings on 9 August 2022
  • Canaccord Annual Growth Conference: presentation at 8:30 am ET on 10 August 2022 and host investor meetings

A live audio webcast of each event will be accessible from the "Events" page of the Investors section of the COMPASS website. Each replay of the webcast will be accessible for 30 days following each event. For more information, please visit ir.compasspathways.com.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa

Multi-centre, d ouble-blind randomised controlled phase II trial will investigate the efficacy of COMP360 psilocybin therap y in anorexia nervosa for which there is currently no approved pharmacological treatment option


News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Gwella Mushrooms CEO Peter Reitano

Gwella Mushrooms CEO Peter Reitano: Early Stage Traction, Revenue and a Great Path to Profitability

Gwella Mushrooms CEO Peter Reitano: Early Stage Traction, Revenue and a Great Path to Profitabilityyoutu.be

Keep reading...Show less

Latest Press Releases

Related News

×